Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2010

View Archived Issues

HemaQuest begins phase II HQK-1004 trial in EBV-related malignancies

Domain Therapeutics claims new adenosine A2A receptor antagonists

Avalon Pharma discloses new modulators of gene expression

Bristol-Myers Squibb describes new inhibitors of beta-amyloid production

Abbott claims new PARP-1 inhibitors

Rigel Pharmaceuticals discovers new PKC inhibitors

Starpharma begins phase II trial of VivaGel in bacterial vaginosis

Serum PICP level may predict profibrotic state and risk of hypertrophic cardiomyopathy

Beta-amyloid(1-42)/P-tau181P biomarker mixture model detects Alzheimer's disease pathology

Probenecid and cilastatin reduce cardiac fibrosis and myocyte hypertrophy ex vivo

Zoniporide exhibits cardioprotective effect in preclinical study

In vitro repopulation of lung matrix yields bioartificial lungs suitable for in vivo implantation

European Commission grants orphan designation to Vertex's cystic fibrosis candidate

Lilly reports key events of past quarter

BiondVax obtains approval for phase II trial of universal influenza vaccine

Cryo-Cell and Monash University enter into autoimmune disease collaboration

Mesoblast provides update on phase III bone marrow transplant program

Palatin Technologies reports phase I safety data on bremelanotide in ED

Medtronic complements bone healing portfolio with Osteotech acquisition

European Commission grants midostaurin orphan drug status in mastocytosis

Lilly decides to halt development of semagacestat for AD

BioMarin to evaluate neuropsychiatric effects of Kuvan in phase IIIb trial in PKU

Depomed to begin phase III trial of Serada for menopausal hot flashes

Oxford BioMedica and Emergent announce licensing agreement

Phylogica and MedImmune join to identify antimicrobial peptides

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...